Alzamend Neuro, Inc.

What they do

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company's pipeline consists of two therapeutic drug candidates: AL001, an ionic cocrystal of lithium, and ALZN002, a cell-based therapeutic vaccine. Both candidates are licensed exclusively from the University of South Florida Research Foundation and are in clinical development.

Revenue drivers

• AL001 — AL001 is the lead product candidate, an ionic cocrystal of lithium designed to treat Alzheimer's, BD, MDD, and PTSD. It is licensed from the University of South Florida and currently in clinical development; no commercial revenue has been generated.
• ALZN002 — ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine for Alzheimer's. It is also licensed exclusively from the University of South Florida and is in clinical development, with no revenue to date.

Recent performance

For the fiscal year ended April 30, 2026, Alzamend reported a net loss of $8.8 million and diluted EPS of -$2.63. Operating cash flow was -$8.1 million. As of April 30, 2026, the company had $711,000 in cash and cash equivalents, total assets of $2.1 million, and shareholder equity of $733,211. Management stated that existing cash is not sufficient to fund operations for the next twelve months.

Strategy

Alzamend's strategy is to advance its two product candidates through clinical development and, if successful, seek FDA approval and commercialize them. The company aims to conduct Phase II clinical trials for AL001 in Alzheimer's, BD, MDD, and PTSD, and to complete the Phase I/IIA clinical trial for ALZN002. To fund these activities, Alzamend plans to raise additional capital through equity offerings, licensing arrangements, or other sources.

Risks

• Insufficient capital for operations — As of April 30, 2026, the company had only $711,000 in cash and believes this is not enough to fund operations for the next twelve months.
• Early-stage clinical development — Both AL001 and ALZN002 are in clinical development with no approved products, making the company dependent on successful trial outcomes and regulatory approvals.
• Delisting risk — Alzamend received delisting notices from its exchange in March and August 2026, indicating potential non-compliance with listing standards.
• Reliance on licensed intellectual property — The company's entire pipeline is based on exclusive licenses from the University of South Florida Research Foundation, and loss of these licenses would halt development.

Outlook

Management expects expenses to increase substantially as it continues non-clinical research and clinical development, including Phase II trials for AL001 and the Phase I/IIA trial for ALZN002. The company acknowledges that it will need substantial additional funding to complete development and any commercialization. If additional capital is not obtained, Alzamend may be forced to delay, reduce, or eliminate its development programs.